1,1'-Carbonyl-di-(1,2,4-triazole) → 6-(2-oxa-5-azaspiro[3.4]octan-5-ylmethyl)-N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-(dimethoxymethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

HRID 1777971ノート

反応式

HRID 1777971 の反応式
N1([C:6](N2C=NC=N2)=[O:7])C=NC=N1.[NH2:13][C:14]1[CH:21]=[C:20]([NH:22][CH2:23][CH2:24][O:25][CH3:26])[C:17]([C:18]#[N:19])=[CH:16][N:15]=1.[CH3:27][O:28][CH:29]([O:49][CH3:50])[C:30]1[C:39]([CH2:40][N:41]2[CH2:48][CH2:47][CH2:46][C:42]32[CH2:45][O:44][CH2:43]3)=[CH:38][C:37]2[CH2:36][CH2:35][CH2:34][NH:33][C:32]=2[N:31]=1>CN(C=O)C>[CH2:43]1[C:42]2([CH2:46][CH2:47][CH2:48][N:41]2[CH2:40][C:39]2[CH:38]=[C:37]3[C:32](=[N:31][C:30]=2[CH:29]([O:28][CH3:27])[O:49][CH3:50])[N:33]([C:6]([NH:13][C:14]2[CH:21]=[C:20]([NH:22][CH2:23][CH2:24][O:25][CH3:26])[C:17]([C:18]#[N:19])=[CH:16][N:15]=2)=[O:7])[CH2:34][CH2:35][CH2:36]3)[CH2:45][O:44]1

参加物

5

反応物 3

HCID 43939611,1'-Carbonyl-di-(1,2,4-triazole)HCID 1180367515-((2-(Dimethoxymethyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)methyl)-2-oxa-5-azaspiro[3.4]octane2 回HCID 1180369516-Amino-4-((2-methoxyethyl)amino)nicotinonitrile2 回

生成物 1

HCID 1180366486-(2-oxa-5-azaspiro[3.4]octan-5-ylmethyl)-N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-(dimethoxymethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒3 回

実験手順

A solution of di(1H-1,2,4-triazol-1-yl)methanone (320 mg, 1.95 mmol) in DMF (7 ml) was added to a mixture of 6-amino-4-((2-methoxyethyl)amino)nicotinonitrile (intermediate 75, 375 mg, 1.95 mmol) in anhydrous DMF (1.5 ml) at 0° C. After stirring for 2.5 h at room temperature a solution of 5-((2-(dimethoxymethyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)methyl)-2-oxa-5-azaspiro[3.4]octane (intermediate 230C, 260 mg, 0.78 mmol) in DMF (3 ml) was added. The reaction mixture was stirred for 17.5 h at room temperature, then partitioned between saturated aqueous NaHCO3 solution and EtOAc, the EtOAc phase washed with brine, dried over MgSO4 and evaporated. The residue was applied to a silica column and purified by normal phase chromatography, eluting with EtOAc then a gradient from DCM to 10% MeOH in DCM. Product containing fractions were combined and evaporated to give the title compound as a pale yellow solid. (UPLC-MS 3) Rt=0.92 min; MS m/z [M+H]+ 552.

後処理

  1. additionwas added
  2. custompartitioned between saturated aqueous NaHCO3 solution and EtOAc
  3. washthe EtOAc phase washed with brine
  4. dry with materialdried over MgSO4
  5. customevaporated
  6. custompurified by normal phase chromatography
  7. washeluting with EtOAc
  8. additionProduct containing fractions
  9. customevaporated

出典と根拠

ORDレコード
ord-80511d67107f48ddb10aec586b95e508
出典データセット
uspto-grants-2016_02
特許番号
US09266883B2

反応ノート

読み込み中…